Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 21

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Mechanism of Action of an EPAC1-Selective Competitive Partial Agonist

Shao, Hongzhao, Mohamed, Hebatallah, Boulton, Stephen, Huang, Jinfeng, Wang, Pingyuan, Chen, Haiying, Zhou, Jia, Luchowska-Stańska, Urszula, Jentsch, Nicholas G., Armstrong, Alison L., Magolan, Jakob, Yarwood, Stephen, Melacini, Giuseppe · 2020 · Journal of Medicinal Chemistry

Abstract

The exchange protein activated by cAMP (EPAC) is a promising drug target for a wide disease range, from neurodegeneration and infections to cancer and cardiovascular conditions. A novel partial agonist of the EPAC isoform 1 (EPAC1), I942, was recently discovered, but its mechanism of action remains poorly understood. Here, we utilize NMR spectroscopy to map the I942–EPAC1 interactions at atomic resolution and propose a mechanism for I942 partial agonism. We found that I942 interacts with the phosphate binding cassette (PBC) and base binding region (BBR) of EPAC1, similar to cyclic adenosine monophosphate (cAMP). These results not only reveal the molecular basis for the I942 vs cAMP mimicry and competition, but also suggest that the partial agonism of I942 arises from its ability to stabilize an inhibition-incompetent activation intermediate distinct from both active and inactive EPAC1 states. The mechanism of action of I942 may facilitate drug design for EPAC-related diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.9b02151

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 80

  1. Kawasaki, 1998, A family of cAMP-binding proteins that directly activate Rap1, Science, 282, 2275, 10.1126/science.282.5397.2275 · DOI · Paper page
  2. de Rooij, 1998, Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP, Nature, 396, 474, 10.1038/24884 · DOI · Paper page
  3. de Rooij, 2000, Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs, J. Biol. Chem., 275, 20829, 10.1074/jbc.M001113200 · DOI · Paper page
  4. Schmidt, 2013, Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions, Pharmacol. Rev., 65, 670, 10.1124/pr.110.003707 · DOI · Paper page
  5. Robichaux, 2018, Intracellular cAMP sensor EPAC: physiology, pathophysiology, and therapeutics development, Physiol. Rev., 98, 919, 10.1152/physrev.00025.2017 · DOI · Paper page
  6. Kaneko, 2004, Presynaptic mechanism underlying cAMP-dependent synaptic potentiation, J. Neurosci., 24, 5202, 10.1523/JNEUROSCI.0999-04.2004 · DOI · Paper page
  7. Yang, 2012, EPAC null mutation impairs learning and social interactions via aberrant regulation of miR-124 and Zif268 translation, Neuron, 73, 774, 10.1016/j.neuron.2012.02.003 · DOI · Paper page
  8. Morel, 2005, cAMP-binding protein Epac induces cardiomyocyte hypertrophy, Circ. Res., 97, 1296, 10.1161/01.RES.0000194325.31359.86 · DOI · Paper page
  9. Métrich, 2008, Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy, Circ. Res., 102, 959, 10.1161/CIRCRESAHA.107.164947 · DOI · Paper page
  10. Laurent, 2015, Exchange protein directly activated by cAMP 1 promotes autophagy during cardiomyocyte hypertrophy, Cardiovasc. Res., 105, 55, 10.1093/cvr/cvu242 · DOI
  11. Rangarajan, 2003, Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor, J. Cell Biol., 160, 487, 10.1083/jcb.200209105 · DOI · Paper page
  12. Bastian, 2009, The inhibitory effect of norepinephrine on the migration of ES-2 ovarian carcinoma cells involves a Rap1-dependent pathway, Cancer Lett., 274, 218, 10.1016/j.canlet.2008.09.008 · doi:10.1016/j.canlet.2008.09.008
  13. Yan, 2013, Enhanced leptin sensitivity, reduced adiposity, and improved glucose homeostasis in mice lacking exchange protein directly activated by cyclic AMP isoform 1, Mol. Cell. Biol., 33, 918, 10.1128/MCB.01227-12 · DOI
  14. Almahariq, 2015, Pharmacological inhibition and genetic knockdown of exchange protein directly activated by cAMP 1 reduce pancreatic cancer metastasis in vivo, Mol. Pharmacol., 87, 142, 10.1124/mol.114.095158 · doi:10.1124/mol.114.095158
  15. Hu, 2016, Role of exchange protein directly activated by cyclic AMP isoform 1 in energy homeostasis: regulation of leptin expression and secretion in white adipose tissue, Mol. Cell. Biol., 36, 2440, 10.1128/MCB.01034-15 · DOI
  16. Gao, 2016, Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo, Med. Oncol., 33, 10.1007/s12032-016-0786-0 · DOI
  17. Kumar, 2017, Role of exchange protein directly activated by cAMP (EPAC1) in breast cancer cell migration and apoptosis, Mol. Cell. Biochem., 430, 115, 10.1007/s11010-017-2959-3 · doi:10.1007/s11010-017-2959-3
  18. Hwang, 2017, Epac2a-null mice exhibit obesity-prone nature more susceptible to leptin resistance, Int. J. Obes., 41, 279, 10.1038/ijo.2016.208 · DOI
  19. Almahariq, 2013, A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion, Mol. Pharmacol., 83, 122, 10.1124/mol.112.080689 · DOI · Paper page
  20. Wang, 2017, Lithium and an EPAC-specific inhibitor ESI-09 synergistically suppress pancreatic cancer cell proliferation and survival, Acta Biochim. Biophys. Sin., 49, 573, 10.1093/abbs/gmx045 · DOI
  21. Gong, 2013, Exchange protein directly activated by cAMP plays a critical role in bacterial invasion during fatal rickettsioses, Proc. Natl. Acad. Sci. U.S.A., 110, 19615, 10.1073/pnas.1314400110 · DOI
  22. Tao, 2014, Blocking of exchange proteins directly activated by cAMP leads to reduced replication of Middle East respiratory syndrome coronavirus, J. Virol., 88, 3902, 10.1128/JVI.03001-13 · DOI
  23. Dawn, 2014, The central role of cAMP in regulating Plasmodium falciparum merozoite invasion of human erythrocytes, PLoS Pathog., 10, 10.1371/journal.ppat.1004520 · DOI
  24. McPhee, 2005, Cyclic nucleotide signalling: a molecular approach to drug discovery for Alzheimer’s disease, Biochem. Soc. Trans., 33, 1330, 10.1042/BST0331330 · doi:10.1042/bst0331330
  25. Singhmar, 2016, Critical role for Epac1 in inflammatory pain controlled by GRK2-mediated phosphorylation of Epac1, Proc. Natl. Acad. Sci. U.S.A., 113, 3036, 10.1073/pnas.1516036113 · DOI
  26. Wang, 2013, Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain, J. Clin. Invest., 123, 5023, 10.1172/JCI66241 · DOI
  27. Wan, 2014, Activation of exchange protein activated by cAMP in the rat basolateral amygdala impairs reconsolidation of a memory associated with self-administered cocaine, PLoS ONE, 9, 10.1371/journal.pone.0107359 · DOI
  28. Bos, 2006, Epac proteins: multi-purpose cAMP targets, Trends Biochem. Sci., 31, 680, 10.1016/j.tibs.2006.10.002 · DOI · Paper page
  29. Rehmann, 2006, Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state, Nature, 439, 625, 10.1038/nature04468 · DOI · Paper page
  30. Mazhab-Jafari, 2007, Understanding cAMP-dependent allostery by NMR spectroscopy: comparative analysis of the EPAC1 cAMP-binding domain in its apo and cAMP-bound states, J. Am. Chem. Soc., 129, 14482, 10.1021/ja0753703 · DOI
  31. VanSchouwen, 2011, Role of dynamics in the autoinhibition and activation of the exchange protein directly activated by cyclic AMP (EPAC), J. Biol. Chem., 286, 42655, 10.1074/jbc.M111.277723 · DOI
  32. Das, 2008, Entropy-driven cAMP-dependent allosteric control of inhibitory interactions in exchange proteins directly activated by cAMP, J. Biol. Chem., 283, 19691, 10.1074/jbc.M802164200 · DOI
  33. Rehmann, 2008, Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B, Nature, 455, 124, 10.1038/nature07187 · DOI · Paper page
  34. Rehmann, 2003, Structure and regulation of the cAMP-binding domains of Epac2, Nat. Struct. Biol., 10, 26, 10.1038/nsb878 · DOI · Paper page
  35. Kraemer, 2001, Dynamic interaction of cAMP with the Rap guanine-nucleotide exchange factor Epac1, J. Mol. Biol., 306, 1167, 10.1006/jmbi.2001.4444 · DOI
  36. Kukic, 2015, Structure and dynamics of the integrin LFA-1 I-domain in the inactive state underlie its inside-out/outside-in signaling and allosteric mechanisms, Structure, 23, 745, 10.1016/j.str.2014.12.020 · DOI
  37. Gagné, 2015, Network of long-range concerted chemical shift displacements upon ligand binding to human angiogenin, Protein Sci., 24, 525, 10.1002/pro.2613 · DOI
  38. Cembran, 2014, NMR mapping of protein conformational landscapes using coordinated behavior of chemical shifts upon ligand binding, Phys. Chem. Chem. Phys., 16, 6508, 10.1039/C4CP00110A · DOI · Paper page
  39. De, 2012, Complete thermodynamic and kinetic characterization of the isomer-specific interaction between Pin1-WW domain and the amyloid precursor protein cytoplasmic tail phosphorylated at Thr668, Biochemistry, 51, 8583, 10.1021/bi3008214 · DOI
  40. Boehr, 2009, The role of dynamic conformational ensembles in biomolecular recognition, Nat. Chem. Biol., 5, 789, 10.1038/nchembio.232 · DOI · Paper page
  41. de Simone, 2015, Structure of a low-population intermediate state in the release of an enzyme product, eLife, 4, 10.7554/eLife.02777 · DOI
  42. Selvaratnam, 2012, The projection analysis of NMR chemical shifts reveals extended EPAC autoinhibition determinants, Biophys. J., 102, 630, 10.1016/j.bpj.2011.12.030 · DOI
  43. Tsalkova, 2012, Isoform-specific antagonists of exchange proteins directly activated by cAMP, Proc. Natl. Acad. Sci. U.S.A., 109, 18613, 10.1073/pnas.1210209109 · DOI
  44. Zhu, 2015, Biochemical and pharmacological characterizations of ESI-09 based EPAC inhibitors: defining the ESI-09 “therapeutic window”, Sci. Rep., 5, 10.1038/srep09344 · DOI
  45. Brown, 2014, Identification and validation of modulators of exchange protein activated by cAMP (Epac) activity: structure-function implications for Epac activation and inhibition, J. Biol. Chem., 289, 8217, 10.1074/jbc.M114.548636 · DOI
  46. Brown, 2014, Allosteric inhibition of Epac: computational modeling and experimental validation to identify allosteric sites and inhibitors, J. Biol. Chem., 289, 29148, 10.1074/jbc.M114.569319 · doi:10.1074/jbc.m114.569319
  47. Laudette, 2019, Identification of a pharmacological inhibitor of Epac1 that protects the heart against acute and chronic models of cardiac stress, Cardiovasc. Res., 115, 1766, 10.1093/cvr/cvz076 · DOI
  48. Courilleau, 2012, Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac, J. Biol. Chem., 287, 44192, 10.1074/jbc.M112.422956 · DOI
  49. Courilleau, 2013, The R-enantiomer of CE3F4 is a preferential inhibitor of human exchange protein directly activated by cyclic AMP isoform 1 (Epac1), Biochem. Biophys. Res. Commun., 440, 443, 10.1016/j.bbrc.2013.09.107 · DOI
  50. Sonawane, 2017, Structure-activity relationship studies with tetrahydroquinoline analogs as EPAC inhibitors, ACS Med. Chem. Lett., 8, 1183, 10.1021/acsmedchemlett.7b00358 · doi:10.1021/acsmedchemlett.7b00358
  51. Boulton, 2018, Mechanism of selective enzyme inhibition through uncompetitive regulation of an allosteric agonist, J. Am. Chem. Soc., 140, 9624, 10.1021/jacs.8b05044 · doi:10.1021/jacs.8b05044
  52. Ahmed, 2019, Recent advances in EPAC-targeted therapies: a biophysical perspective, Cells, 8, 1462, 10.3390/cells8111462 · doi:10.3390/cells8111462
  53. Parnell, 2017, Identification of a novel, small molecule partial agonist for the cyclic AMP sensor, EPAC1, Sci. Rep., 7, 10.1038/s41598-017-00455-7 · DOI
  54. Schwede, 2000, Cyclic nucleotide analogs as biochemical tools and prospective drugs, Pharmacol. Ther., 87, 199, 10.1016/S0163-7258(00)00051-6 · DOI · Paper page
  55. Enserink, 2002, A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK, Nat. Cell Biol., 4, 901, 10.1038/ncb874 · DOI · Paper page
  56. Christensen, 2003, cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension, J. Biol. Chem., 278, 35394, 10.1074/jbc.M302179200 · DOI · Paper page
  57. Rehmann, 2003, Ligand-mediated activation of the cAMP-responsive guanine nucleotide exchange factor Epac, J. Biol. Chem., 278, 38548, 10.1074/jbc.M306292200 · DOI
  58. Poppe, 2008, Cyclic nucleotide analogs as probes of signaling pathways, Nat. Methods, 5, 277, 10.1038/nmeth0408-277 · DOI · Paper page
  59. Vliem, 2008, 8-pCPT-2′-O-Me-cAMP-AM: an improved Epac-selective cAMP analogue, ChemBioChem, 9, 2052, 10.1002/cbic.200800216 · DOI
  60. Dodge-Kafka, 2005, The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways, Nature, 437, 574, 10.1038/nature03966 · DOI · Paper page
  61. Conti, 2007, Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling, Annu. Rev. Biochem., 76, 481, 10.1146/annurev.biochem.76.060305.150444 · DOI · Paper page
  62. Wiejak, 2019, The novel exchange protein activated by cyclic AMP 1 (EPAC1) agonist, I942, regulates inflammatory gene expression in human umbilical vascular endothelial cells (HUVECs), Biochim. Biophys. Acta Mol. Cell Res., 1866, 264, 10.1016/j.bbamcr.2018.11.004 · DOI
  63. Barker, 2017, The potential of a novel class of EPAC-selective agonists to combat cardiovascular Inflammation, J. Cardiovasc. Dev. Dis., 4, 22, 10.3390/jcdd4040022 · DOI
  64. Tsalkova, 2012, A fluorescence-based high-throughput assay for the discovery of exchange protein directly activated by cyclic AMP (EPAC) antagonists, PLoS ONE, 7, 10.1371/journal.pone.0030441 · DOI
  65. Boulton, 2019, Mechanisms of specific versus nonspecific interactions of aggregation-prone inhibitors and attenuators, J. Med. Chem., 62, 5063, 10.1021/acs.jmedchem.9b00258 · DOI
  66. Selvaratnam, 2011, Mapping allostery through the covariance analysis of NMR chemical shifts, Proc. Natl. Acad. Sci. U.S.A., 108, 6133, 10.1073/pnas.1017311108 · DOI · Paper page
  67. Eghbalnia, 2005, Protein energetic conformational analysis from NMR chemical shifts (PECAN) and its use in determining secondary structural elements, J. Biomol. NMR, 32, 71, 10.1007/s10858-005-5705-1 · DOI
  68. Zwahlen, 1997, Methods for measurement of intermolecular NOEs by multinuclear NMR spectroscopy: application to a bacteriophage λ N-peptide/ boxB RNA complex, J. Am. Chem. Soc., 119, 6711, 10.1021/ja970224q · DOI · Paper page
  69. Melacini, 2000, Separation of intra- and intermolecular NOEs through simultaneous editing and J -compensated filtering: A 4D quadrature-free constant-time J -resolved approach, J. Am. Chem. Soc., 122, 9735, 10.1021/ja0015996 · doi:10.1021/ja0015996
  70. Medek, 2000, The use of differential chemical shifts for determining the binding site location and orientation of protein-bound ligands, J. Am. Chem. Soc., 122, 1241, 10.1021/ja993921m · DOI
  71. Mayer, 2001, Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor, J. Am. Chem. Soc., 123, 6108, 10.1021/ja0100120 · DOI · Paper page
  72. Das, 2009, Dynamically driven ligand selectivity in cyclic nucleotide binding domains, J. Biol. Chem., 284, 23682, 10.1074/jbc.M109.011700 · DOI
  73. Delaglio, 1995, NMRPipe: a multidimensional spectral processing system based on UNIX pipes, J. Biomol. NMR, 6, 277, 10.1007/BF00197809 · DOI · Paper page
  74. Goddard, 2008, Sparky 3
  75. Yamazaki, 1995, NMR pulse schemes for the sequence-specific assignment of arginine guanidino 15N and 1H chemical shifts in proteins, J. Am. Chem. Soc., 117, 3556, 10.1021/ja00117a025 · doi:10.1021/ja00117a025
  76. Wang, 1995, An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule, FEBS Lett., 360, 111, 10.1016/0014-5793(95)00062-E · DOI · Paper page
  77. Byun, 2018, NMR methods to dissect the molecular mechanisms of disease-related mutations (DRMs): Understanding how DRMs remodel functional free energy landscapes, Methods, 148, 19, 10.1016/j.ymeth.2018.05.018 · DOI · Paper page
  78. de Hoon, 2004, Open source clustering software, Bioinformatics, 20, 1453, 10.1093/bioinformatics/bth078 · DOI · Paper page
  79. VanSchouwen, 2015, Mechanism of cAMP partial agonism in protein kinase G (PKG), J. Biol. Chem., 290, 28631, 10.1074/jbc.M115.685305 · DOI
  80. Boulton, 2016, Advances in NMR methods to map allosteric sites: from models to translation, Chem. Rev., 116, 6267, 10.1021/acs.chemrev.5b00718 · DOI · Paper page

Cited by

See all 21

Metadata

Authors
Shao, H., Mohamed, H., Boulton, S., Huang, J., Wang, P., Chen, H., Zhou, J., Luchowska-Stańska, U., Jentsch, N. G., Armstrong, A. L., Magolan, J., Yarwood, S., & Melacini, G.
Affiliations
  • McMaster University , , , ,
  • University of Texas Medical Branch , , , ,
  • Heriot-Watt University , , Edinburgh Campus , ,
Venue
Journal of Medicinal Chemistry
Published
2020-04-16
Volume
63
Issue
9
Pages
4762-4775
ISSN
  • 0022-2623
  • 1520-4804
Cited by
21
References
1
Language
en
Funders
  • Canadian Institutes of Health Research (389522)
  • Natural Sciences and Engineering Research Council of Canada (RGPIN-2019-05990)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.